These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 19284526)
1. Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Matta A; Ralhan R Head Neck Oncol; 2009 Mar; 1():6. PubMed ID: 19284526 [TBL] [Abstract][Full Text] [Related]
2. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives. Bozec A; Peyrade F; Milano G Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267 [TBL] [Abstract][Full Text] [Related]
3. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma. Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792 [TBL] [Abstract][Full Text] [Related]
4. Toward the use of precision medicine for the treatment of head and neck squamous cell carcinoma. Gong W; Xiao Y; Wei Z; Yuan Y; Qiu M; Sun C; Zeng X; Liang X; Feng M; Chen Q Oncotarget; 2017 Jan; 8(2):2141-2152. PubMed ID: 27924064 [TBL] [Abstract][Full Text] [Related]
5. Integration of molecular targeted therapy with radiation in head and neck cancer. Du Y; Peyser ND; Grandis JR Pharmacol Ther; 2014 Apr; 142(1):88-98. PubMed ID: 24280066 [TBL] [Abstract][Full Text] [Related]
6. EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Freudlsperger C; Burnett JR; Friedman JA; Kannabiran VR; Chen Z; Van Waes C Expert Opin Ther Targets; 2011 Jan; 15(1):63-74. PubMed ID: 21110697 [TBL] [Abstract][Full Text] [Related]
7. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC). Cohen RB Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225 [TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy. Uribe P; Gonzalez S Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084 [TBL] [Abstract][Full Text] [Related]
9. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. Masuda M; Suzui M; Lim JT; Deguchi A; Soh JW; Weinstein IB J Exp Ther Oncol; 2002; 2(6):350-9. PubMed ID: 12440226 [TBL] [Abstract][Full Text] [Related]
10. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma. Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343 [TBL] [Abstract][Full Text] [Related]
11. Molecular pathways in head and neck cancer: EGFR, PI3K, and more. Psyrri A; Seiwert TY; Jimeno A Am Soc Clin Oncol Educ Book; 2013; ():246-55. PubMed ID: 23714515 [TBL] [Abstract][Full Text] [Related]
12. Targeted therapy in head and neck cancer. Kundu SK; Nestor M Tumour Biol; 2012 Jun; 33(3):707-21. PubMed ID: 22373581 [TBL] [Abstract][Full Text] [Related]
13. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer. Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254 [TBL] [Abstract][Full Text] [Related]
14. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis. Lu H; Li X; Lu Y; Qiu S; Fan Z Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723 [TBL] [Abstract][Full Text] [Related]
15. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation. Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469 [TBL] [Abstract][Full Text] [Related]
16. Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer. Bozec A; Ebran N; Radosevic-Robin N; Sudaka A; Monteverde M; Toussan N; Etienne-Grimaldi MC; Nigro CL; Merlano M; Penault-Llorca F; Milano G Laryngoscope; 2016 Apr; 126(4):E156-63. PubMed ID: 26597440 [TBL] [Abstract][Full Text] [Related]
17. Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. Egloff AM; Grandis JR Semin Oncol; 2008 Jun; 35(3):286-97. PubMed ID: 18544443 [TBL] [Abstract][Full Text] [Related]
18. Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma. Kao J; Sikora AT; Fu S Curr Cancer Drug Targets; 2009 Dec; 9(8):931-7. PubMed ID: 20025602 [TBL] [Abstract][Full Text] [Related]
19. Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma. Michmerhuizen NL; Leonard E; Matovina C; Harris M; Herbst G; Kulkarni A; Zhai J; Jiang H; Carey TE; Brenner JC Mol Pharmacol; 2019 May; 95(5):528-536. PubMed ID: 30858165 [TBL] [Abstract][Full Text] [Related]
20. Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma. Isaacsson Velho PH; Castro G; Chung CH Am Soc Clin Oncol Educ Book; 2015; ():123-8. PubMed ID: 25993150 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]